Risky decision-making following prefrontal D1 receptor manipulation.
Iowa gambling task
bipolar disorder
lentivirus
mania
rat
Journal
Translational neuroscience
ISSN: 2081-3856
Titre abrégé: Transl Neurosci
Pays: Germany
ID NLM: 101550327
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
received:
03
08
2021
revised:
13
09
2021
accepted:
13
09
2021
entrez:
11
11
2021
pubmed:
12
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
The prefrontal dopamine D1 receptor (D1R) is involved in cognitive processes. Viral overexpression of this receptor in rats further increases the reward-related behaviors and even its termination induces anhedonia and helplessness. In this study, we investigated the risky decision-making during D1R overexpression and its termination. Rats conducted the rodent version of the Iowa gambling task daily. In addition, the methyl CpG-binding protein-2 (MeCP2), one regulator connecting the dopaminergic system, cognitive processes, and mood-related behavior, was investigated after completion of the behavioral tasks. D1R overexpressing subjects exhibited maladaptive risky decision-making and risky decisions returned to control levels following termination of D1R overexpression; however, after termination, animals earned less reward compared to control subjects. In this phase, MeCP2-positive cells were elevated in the right amygdala. Our results extend the previously reported behavioral changes in the D1R-manipulated animal model to increased risk-taking and revealed differential MeCP2 expression adding further evidence for a bipolar disorder-like phenotype of this model.
Identifiants
pubmed: 34760299
doi: 10.1515/tnsci-2020-0187
pii: tnsci-2020-0187
pmc: PMC8569284
doi:
Types de publication
Journal Article
Langues
eng
Pagination
432-443Informations de copyright
© 2021 Dominik K. E. Beyer et al., published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest: Authors state no conflict of interest.
Références
J Neurosci. 2013 Nov 6;33(45):17617-23
pubmed: 24198353
Brain. 2016 Sep;139(Pt 9):2554-66
pubmed: 27368345
Nat Commun. 2019 Jan 15;10(1):223
pubmed: 30644390
Br J Psychiatry. 2009 Sep;195(3):194-201
pubmed: 19721106
Psychopharmacology (Berl). 2006 Oct;188(2):228-35
pubmed: 16915385
J Affect Disord. 2017 Aug 1;217:205-209
pubmed: 28415008
Neuropsychologia. 2016 Oct;91:163-172
pubmed: 27475264
J Neurosci. 2009 Apr 1;29(13):4218-27
pubmed: 19339616
Nat Neurosci. 2010 Sep;13(9):1128-36
pubmed: 20711186
Science. 1997 Feb 28;275(5304):1293-5
pubmed: 9036851
Neuropharmacology. 2014 Feb;77:208-16
pubmed: 24120838
Br J Psychiatry. 2015 Oct;207(4):328-33
pubmed: 26089303
J Neurosci Methods. 2008 Oct 30;175(1):104-7
pubmed: 18765252
Addiction. 2011 Feb;106(2):383-90
pubmed: 20883460
Biol Psychiatry. 2001 Jan 15;49(2):97-109
pubmed: 11164756
Neuroscience. 2018 Jan 15;369:212-221
pubmed: 29155278
Sci Rep. 2017 Jun 19;7(1):3809
pubmed: 28630404
Hum Gene Ther. 2004 Oct;15(10):934-44
pubmed: 15585109
Psychopharmacology (Berl). 1992;106(1):14-8
pubmed: 1531387
Virology. 1999 Jan 20;253(2):193-207
pubmed: 9918878
J Affect Disord. 1999 May;53(2):109-22
pubmed: 10360405
Learn Mem. 2006 Nov-Dec;13(6):777-82
pubmed: 17142306
Psychiatry Res. 2008 Nov 30;161(2):142-52
pubmed: 18848361
Hum Brain Mapp. 2020 Aug 15;41(12):3358-3369
pubmed: 32386113
Gene Ther. 2001 Dec;8(24):1817-25
pubmed: 11821934
Can J Psychiatry. 1997 Jun;42(5):467-75
pubmed: 9220109
PLoS One. 2012;7(5):e37306
pubmed: 22624011
Biol Sex Differ. 2020 Feb 22;11(1):8
pubmed: 32087746
Front Neurosci. 2011 Oct 10;5:109
pubmed: 22013406
J Vis Exp. 2012 Jul 30;(65):
pubmed: 22871843
Bipolar Disord. 2012 Jun;14(4):356-74
pubmed: 22631620
J Neurosci Methods. 1980 Dec;3(2):129-49
pubmed: 6110810
Int J Bipolar Disord. 2017 Oct 13;5(1):35
pubmed: 29027157
Psychopharmacology (Berl). 2014 Apr;231(8):1615-26
pubmed: 24408208
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Neurosci. 2015 Apr 15;35(15):6209-20
pubmed: 25878291
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17951-6
pubmed: 19822738
Neuropsychopharmacology. 2016 Dec;41(13):3016-3024
pubmed: 27356764
Neuropsychopharmacology. 2014 Dec;39(13):3112-22
pubmed: 25005251
Biol Psychiatry. 2018 Jun 15;83(12):1036-1043
pubmed: 28728675
Neuroimage. 2014 Nov 1;101:448-57
pubmed: 25038436
J Affect Disord. 2016 Apr;194:72-9
pubmed: 26803778
Biol Psychiatry. 2009 Oct 15;66(8):743-9
pubmed: 19482266
Biol Psychiatry. 2013 Dec 15;74(12):908-16
pubmed: 23684382
J Psychopharmacol. 2011 Jul;25(7):934-43
pubmed: 21421642
Cognition. 1994 Apr-Jun;50(1-3):7-15
pubmed: 8039375
J Neurosci. 2008 Mar 5;28(10):2375-82
pubmed: 18322084
Psychiatry Res. 2015 Dec 30;230(3):835-8
pubmed: 26564549
Exp Neurol. 2018 Sep;307:74-81
pubmed: 29782864
Biol Psychiatry. 2011 Aug 15;70(4):357-65
pubmed: 21429477
Int J Bipolar Disord. 2021 Mar 8;9(1):9
pubmed: 33683478
Synapse. 2000 Aug;37(2):167-9
pubmed: 10881038
Cell Mol Neurobiol. 2019 Jan;39(1):31-59
pubmed: 30446950
Int Rev Psychiatry. 2009;21(4):323-35
pubmed: 20374147
J Clin Child Adolesc Psychol. 2012;41(6):803-10
pubmed: 22540428
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:314-321
pubmed: 28830794
J Affect Disord. 2013 Aug 15;150(1):50-6
pubmed: 23489397
Sci Rep. 2018 Mar 14;8(1):4533
pubmed: 29540721
Mol Cell Neurosci. 2004 Nov;27(3):306-21
pubmed: 15519245
J Int Neuropsychol Soc. 2013 Apr;19(4):474-82
pubmed: 23410848
Psychopharmacology (Berl). 2016 Apr;233(7):1191-201
pubmed: 26762379
Nat Neurosci. 2005 Feb;8(2):147-8
pubmed: 15643429
Neurosci Biobehav Rev. 2015 Nov;58:4-18
pubmed: 26297513
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Dialogues Clin Neurosci. 2016 Mar;18(1):55-63
pubmed: 27069380
Int J Neuropsychopharmacol. 2017 Dec 1;20(12):1036-1046
pubmed: 29106542
J Neurosci. 2020 May 6;40(19):3799-3814
pubmed: 32269107
Acta Psychiatr Scand Suppl. 2007;(434):41-9
pubmed: 17688462
Bipolar Disord. 2004 Jun;6(3):183-96
pubmed: 15117397
Psychiatry Res. 2013 Dec 30;210(3):1324-5
pubmed: 24001587
J Cereb Blood Flow Metab. 2012 Jul;32(7):1248-58
pubmed: 22234338